| HER2/EGFR in Cancer Research | Lifetime | 2 | BE 1 | 99.96 |
| Cancer Treatment and Pharmacology | Lifetime | 6 | BE 2 | 99.97 |
| Breast Cancer Treatment Studies | Lifetime | 6 | BE 1 | 99.95 |
| Advanced Breast Cancer Therapies | Lifetime | 6 | BE 1 | 99.90 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 62 | BE 1 | 99.83 |
| Cancer Genomics and Diagnostics | Lifetime | 71 | BE 1 | 99.79 |
| Peptidase Inhibition and Analysis | Lifetime | 65 | BE 1 | 99.67 |
| Cancer Cells and Metastasis | Lifetime | 169 | BE 2 | 99.11 |
| Estrogen and related hormone effects | Lifetime | 175 | BE 2 | 99.22 |
| Economic and Financial Impacts of Cancer | Lifetime | 85 | BE 1 | 98.50 |
| Ovarian cancer diagnosis and treatment | Lifetime | 287 | BE 5 | 98.68 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 74 | BE 3 | 98.15 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 179 | BE 1 | 98.37 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 152 | BE 5 | 97.88 |
| Neutropenia and Cancer Infections | Lifetime | 209 | BE 4 | 97.91 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 985 | BE 11 | 98.00 |
| Gene expression and cancer classification | Lifetime | 287 | BE 7 | 97.30 |
| Colorectal Cancer Treatments and Studies | Lifetime | 739 | BE 10 | 97.86 |
| Molecular Biology Techniques and Applications | Lifetime | 697 | BE 8 | 95.47 |
| BRCA gene mutations in cancer | Lifetime | 701 | BE 6 | 95.88 |
| Chemotherapy-related skin toxicity | Lifetime | 240 | BE 4 | 92.41 |
| Chemotherapy-induced organ toxicity mitigation | Lifetime | 242 | BE 1 | 91.61 |
| Cancer-related cognitive impairment studies | Lifetime | 930 | BE 13 | 84.33 |
| Breast Cancer Treatment Studies | 2021-2025 | 39 | BE 3 | 99.45 |
| HER2/EGFR in Cancer Research | 2021-2025 | 39 | BE 2 | 99.27 |
| Cancer Treatment and Pharmacology | 2021-2025 | 53 | BE 2 | 98.89 |
| Advanced Breast Cancer Therapies | 2021-2025 | 62 | BE 2 | 98.91 |
| Cancer Genomics and Diagnostics | 2021-2025 | 564 | BE 4 | 96.43 |
| Cancer Cells and Metastasis | 2021-2025 | 327 | BE 10 | 91.24 |
| BRCA gene mutations in cancer | 2021-2025 | 289 | BE 4 | 91.95 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 797 | BE 17 | 90.14 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 833 | BE 8 | 82.65 |
| Cancer Risks and Factors | 2021-2025 | 565 | BE 10 | 81.47 |
| PARP inhibition in cancer therapy | 2021-2025 | 970 | BE 7 | 77.91 |
